PROTEUS Trial Finds Hormone Therapy Beats Single
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- PROTEUS trial — a Phase 3 clinical study of high‑risk, non‑metastatic prostate cancer patients compared two hormone therapy regimens before and after prostatectomy.
- Combined hormone therapy — using two agents pre‑ and post‑surgery — showed superior oncologic outcomes to a single hormone therapy regimen in the trial.
- Antonarakis — a genitourinary oncologist at the University of Minnesota — called the trial’s findings a “watershed moment” in a New England Journal of Medicine editorial.
- Prostate cancer experts — a range of clinicians — interpret the results as a potential new standard of care, adding a third option alongside surgery alone or radiation plus hormone therapy.
Why it matters: High‑risk prostate cancer patients receive a regimen that improves surgical outcomes, and urologists will adopt the combined hormone approach, lowering recurrence and associated treatment expenses.
Ask SkimNews
